Previous 10 | Next 10 |
Molecular Templates ([[MTEM]] +9.5%) has posted its best one-day gain since December after Bank of America initiated the coverage on the stock with a buy rating and a price target of $12.00 per share indicating a premium of ~50.8% to yesterday’s close.The firm calls the company’...
Today’s analyst action includes Intuitive Surgical upgrade at Baird after better-than-expected Q1 earnings and positive catalyst watches opened at Citi on Abbvie and Bristol-Myers Squibb.Intuitive Surgical extends gains as Oppenheimer upgrades the stockIntuitive Surgical (ISRG) is exte...
AUSTIN, Texas, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engine...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to close at record levels Friday, with the Dow Jones hitting 33,800 and the S&P 500 topping 4,100, as investors ignored co...
Shares of Molecular Templates (NASDAQ: MTEM) closed down 23.6% on Monday. The big drop came after the company announced that it was resuming full rights of engineered toxin bodies (ETB) candidate TAK-169 from Takeda (NYSE: TAK) . Molecular Templates also said that it's disco...
Gainers: Chembio Diagnostics (CEMI) +61%.AeroCentury (ACY) +59%.Xcel Brands (XELB) +54%.dMY Technology (DMYD) +34%.Performant Financial (PFMT) +33%.Nephros (NEPH) +27%.Nano-X Imaging (NNOX) +26%.Regional Health Properties (RHE) +24%.Leaf Group (LEAF) +21%.Bluegreen Vacatio...
Shares of Molecular Templates (MTEM) are down 25% after the company announced it was discontinuing development of its lead asset, MT-3724, in diffuse large B-cell lymphoma.MT-3724 is an immunotoxin known as an engineered toxin body ("ETB") that targets CD20.The candidate was first u...
Gainers: Chembio Diagnostics CEMI +60%, Nano-X Imaging NNOX +25%, NanoVibronix (NAOV) +16%, Vivos Therapeutics (VVOS) +15%, Greenwich LifeSciences (GLSI) +14%.Losers: Molecular Templates (MTEM) -26%, ACADIA Pharmaceuticals ACAD -17%,...
Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma Development of First-Generation ETB MT-3724 Has Been Discontinued, Company to Focus on Development of Next-Generation ETB Product Candidates Including Clini...
Today, we take an in-depth name at a small oncology concern named Molecular Templates. It has been busy few months for the firm as it is dealing with an FDA clinical hold, did a secondary offering, and announced an important new partnership. A full investment analysis follows in t...
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...